Evaluating the antidiabetic effects of Chinese herbal medicine: Xiao-Ke-An in 3T3-L1 cells and KKAy mice using both conventional and holistic omics approaches

BMC Complementary and Alternative Medicine

Zheng Li²  Feng Zhang¹  Linli Wang¹  Zhenzhong Yang¹ 

[1]Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

[2]State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China

关键词: Network pharmacology;    TCM;    Xiao-Ke-An;    3T3-L1 cells;    KKAy mice;    Type 2 diabetes mellitus;   

Others  :  1222556
DOI  :  10.1186/s12906-015-0785-2

 received in 2015-04-19, accepted in 2015-07-17,  发布年份 2015

【 摘 要 】

Background

Xiao-Ke-An (XKA) is a Chinese medicine widely used for treating type 2 diabetes mellitus (T2D). It is composed of eight herbal medicines traditionally used for T2D, including Rehmannia glutinosa Libosch, Anemarrhena asphodeloides Bunge, Coptis chinensis Franch, etc. The aim of the present study was to investigate the antidiabetic effects of XKA with both conventional and holistic omics approaches.

Methods

The antidiabetic effect of XKA was first investigated in 3T3-L1 cells to study the effect of XKA on adipogenesis in vitro. Oil Red O staining was performed to determine the lipid accumulation. The intracellular total cholesterol (TC) and triglyceride (TG) contents in XKA treated 3T3-L1 cells were also evaluated. The therapeutic effects of XKA was further evaluated in KKAy mice with both conventional and holistic omics approaches. Body weight, fasting and non-fasting blood glucose, and oral glucose tolerance were measured during the experiment. At the time of sacrifice, serum was collected for the measurement of TG, TC, high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c). The liver, kidney, spleen, pancreas, heart and adipose tissues were harvested and weighted. The liver was used for further microarray experiment. Omics approaches were adopted to evaluate the holistic rebalancing effect of XKA at molecular network level.

Results

XKA significantly inhibited adipogenic differentiation, lowered the intracellular TC and TG contents in 3T3-L1 cells. XKA improved the glucose homeostasis and lipid metabolism, ameliorated insulin resistance in KKAy mice. Futhermore, XKA also exhibited effective therapeutic effects by reversing the molecualr T2D disease network from an unbalanced state.

Conclusions

This study investigated the antidiabetic effects of XKA with both conventional and holistic omics approaches, providing both phenotypic evidence and underlying action mechanisms for the clinical use of XKA treating T2D.

【 授权许可】

   
2015 Yang et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

Fig. 8.

Fig. 9.

【 参考文献 】

• [1]Holman RR. Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive. Nat Rev Endocrinol. 2013; 9(2):67-8.
• [2]Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011; 378(9786):182-97.
• [3]Gu J, Zhang H, Chen L, Xu S, Yuan G, Xu X. Drug–target network and polypharmacology studies of a Traditional Chinese Medicine for type II diabetes mellitus. Comput Biol Chem. 2011; 35(5):293-7.
• [4]Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009; 25(19):2466-72.
• [5]Mopuri R, Ganjayi M, Banavathy KS, Parim BN, Meriga B. Evaluation of anti-obesity activities of ethanolic extract of Terminalia paniculata bark on high fat diet-induced obese rats. BMC Complement Altern Med. 2015; 15(1):76. BioMed Central Full Text
• [6]Azushima K, Tamura K, Wakui H, Maeda A, Ohsawa M, Uneda K, Kobayashi R, Kanaoka T, Dejima T, Fujikawa T et al.. Bofu-Tsu-Shosan, an oriental herbal medicine, exerts a combinatorial favorable metabolic modulation including antihypertensive effect on a mouse model of human metabolic disorders with visceral obesity. PloS One. 2013; 8(10):e75560.
• [7]Etxeberria U, de la Garza AL, Campión J, Martínez JA, Milagro FI. Antidiabetic effects of natural plant extracts via inhibition of carbohydrate hydrolysis enzymes with emphasis on pancreatic alpha amylase. Expert Opin Ther Targets. 2012; 16(3):269-97.
• [8]Qi L-W, Liu E-H, Chu C, Peng Y-B, Cai H-X, Li P. Anti-diabetic agents from natural products—an update from 2004 to 2009. Curr Top Med Chem. 2010; 10(4):434-57.
• [9]Yang Z, Wang Y, Wang Y, Zhang Y. Bioassay-guided screening and isolation of α-glucosidase and tyrosinase inhibitors from leaves of Morus alba. Food Chem. 2012; 131(2):617-25.
• [10]Oh M-R, Park S-H, Kim S-Y, Back H-I, Kim M-G, Jeon J-Y, et al. Postprandial glucose-lowering effects of fermented red ginseng in subjects with impaired fasting glucose or type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. BMC Complement Altern Med. 2014;14.
• [11]Dong M, Gong ZC, Dai XP, Lei GH, Lu HB, Fan L, Qu J, Zhou HH, Liu ZQ. Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2. Clin Exp Pharmacol Physiol. 2011; 38(12):824-9.
• [12]Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H, Lavin MF, Gardiner RA. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 2005; 114(6):950-6.
• [13]Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008; 4(11):682-90.
• [14]Nan Z, Nan H, He Z, Nan J, Liu D. Treatment type 2 diabetes with Xiao-Ke-An, 920 cases of clinical study and experimental animal research. Academic Periodical of Changchun College of Traditional Chinese Medicine. 2005; 21(1):13-5.
• [15]Wang L, Li Z, Zhao X, Liu W, Liu Y, Yang J, et al. A network study of Chinese medicine Xuesaitong injection to elucidate a complex mode of action with multicompound, multitarget, and multipathway. Evid base Compl Alternative Med. 2013;2013.
• [16]Yang Z, Liu W, Zhang F, Li Z, Cheng Y. Deciphering the therapeutic mechanisms of Xiao-Ke-An in treatment of type 2 diabetes in mice by a Fangjiomics approach. Acta Pharmacol Sin. 2015; 36(6):699-707.
• [17]Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res. 2012; 136(1):451-72.
• [18]Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002; 87(6):2764-9.
• [19]Fang H, Harris SC, Su Z, Chen M, Qian F, Shi L, Perkins R, Tong W: ArrayTrack: an FDA and public genomic tool. In: Protein Networks and Pathway Analysis. edn. Edited by Yuri N, Julie B: Springer; 2009: 379-398.
• [20]Wu L, Wang Y, Nie J, Fan X, Cheng Y. A network pharmacology approach to evaluating the efficacy of Chinese medicine using genome-wide transcriptional expression data. Evid Based Complement Alternat Med. 2013;2013.
• [21]Yang Z, Yang J, Liu W, Wu L, Xing L, Wang Y, Fan X, Cheng Y. T2D@ ZJU: a knowledgebase integrating heterogeneous connections associated with type 2 diabetes mellitus. Database. 2013; 2013:bat052.
• [22]Harivenkatesh N, David DC, Haribalaji N, Sudhakar MK. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia a randomized controlled trial. J Cardiovasc Pharmacol Ther. 2014; 19(3):296-303.
• [23]Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011; 27(3):431-2.
• [24]Li P, Qi L-W, Liu E-H, Zhou J-L, Wen X-D. Analysis of Chinese herbal medicines with holistic approaches and integrated evaluation models. TrAC Trends in Analytical Chemistry. 2008; 27(1):66-77.
• [25]Jiang W-Y. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends Pharmacol Sci. 2005; 26(11):558-63.